The predicted potential of quantitative t cell repertoire analysis using next-generation sequencing in anti-PD-L1 treatment in NSCLC patients.

e24220Background: Atezolizumab was the first PD-L1 inhibitor approved by the US Food and Drug Administration (FDA) for patients with metastatic non-small cell lung cancer (mNSCLC) whose disease pro...